Healthcare provider profile · identity verified

Peter F Levins, MD

Family Practice · PHOENIX, AZ · NPI 1407876303

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	296	102
Rosuvastatin Calcium	Rosuvastatin Calcium	206	76
Amlodipine Besylate	Amlodipine Besylate	183	67
Metformin Hcl	Metformin Hcl	151	57
Atorvastatin Calcium	Atorvastatin Calcium	136	54
Pantoprazole Sodium	Pantoprazole Sodium	135	46
Metoprolol Succinate	Metoprolol Succinate	128	42
Lisinopril	Lisinopril	113	44
Losartan Potassium	Losartan Potassium	112	43
Gabapentin	Gabapentin	107	38
Sertraline Hcl	Sertraline Hcl	100	33
Celecoxib	Celecoxib	94	33
Duloxetine Hcl	Duloxetine Hcl	89	29
Tamsulosin Hcl	Tamsulosin Hcl	83	34
Prednisone	Prednisone	80	40
Trazodone Hcl	Trazodone Hcl	71	30
Allopurinol	Allopurinol	68	23
Simvastatin	Simvastatin	65	22
Montelukast Sodium	Montelukast Sodium	62	23
Hydrochlorothiazide	Hydrochlorothiazide	59	24
Escitalopram Oxalate	Escitalopram Oxalate	56	16
Omeprazole	Omeprazole	56	23
Ozempic	Semaglutide	56	14
Furosemide	Furosemide	54	16
Lorazepam	Lorazepam	48	13
Alprazolam	Alprazolam	46	15
Tramadol Hcl	Tramadol Hcl	45	16
Albuterol Sulfate Hfa	Albuterol Sulfate	42	25
Jardiance	Empagliflozin	42	suppressed
Spironolactone	Spironolactone	42	11
Synthroid	Levothyroxine Sodium	41	16
Pioglitazone Hcl	Pioglitazone Hcl	40	14
Zolpidem Tartrate	Zolpidem Tartrate	40	11
Ciprofloxacin Hcl	Ciprofloxacin Hcl	39	24
Clopidogrel	Clopidogrel Bisulfate	39	13
Irbesartan	Irbesartan	38	suppressed
Carvedilol	Carvedilol	35	16
Mounjaro	Tirzepatide	34	suppressed
Eliquis	Apixaban	33	13
Tizanidine Hcl	Tizanidine Hcl	33	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	32	suppressed
Lovastatin	Lovastatin	32	11
Valsartan	Valsartan	32	suppressed
Pravastatin Sodium	Pravastatin Sodium	31	13
Finasteride	Finasteride	30	14
Methocarbamol	Methocarbamol	28	suppressed
Fluconazole	Fluconazole	27	11
Ondansetron Odt	Ondansetron	27	14
Glimepiride	Glimepiride	26	suppressed
Clonazepam	Clonazepam	25	suppressed
Diazepam	Diazepam	25	suppressed
Famotidine	Famotidine	25	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	25	suppressed
Metformin Hcl Er	Metformin Hcl	25	suppressed
Cephalexin	Cephalexin	24	20
Doxycycline Monohydrate	Doxycycline Monohydrate	24	21
Estradiol	Estradiol	24	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	24	11
Azithromycin	Azithromycin	22	12
Citalopram Hbr	Citalopram Hydrobromide	22	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	22	12
Meclizine Hcl	Meclizine Hcl	22	suppressed
Warfarin Sodium	Warfarin Sodium	22	suppressed
Lansoprazole	Lansoprazole	21	suppressed
Methylprednisolone	Methylprednisolone	21	17
Nystatin	Nystatin	21	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	21	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	20	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	20	suppressed
Ipratropium Bromide	Ipratropium Bromide	20	11
Pregabalin	Pregabalin	20	suppressed
Atenolol	Atenolol	19	suppressed
Myrbetriq	Mirabegron	19	suppressed
Potassium Chloride	Potassium Chloride	19	suppressed
Temazepam	Temazepam	19	suppressed
Eszopiclone	Eszopiclone	18	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	18	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Farxiga	Dapagliflozin Propanediol	17	suppressed
Ibandronate Sodium	Ibandronate Sodium	17	suppressed
Ketoconazole	Ketoconazole	17	suppressed
Mupirocin	Mupirocin	17	suppressed
Trulicity	Dulaglutide	16	suppressed
Aripiprazole	Aripiprazole	15	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	15	suppressed
Raloxifene Hcl	Raloxifene Hcl	15	suppressed
Sucralfate	Sucralfate	15	suppressed
Testosterone Cypionate	Testosterone Cypionate	15	suppressed
Trintellix	Vortioxetine Hydrobromide	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	15	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	14	suppressed
Dutasteride	Dutasteride	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Meloxicam	Meloxicam	14	suppressed
Memantine Hcl Er	Memantine Hcl	14	suppressed
Mirtazapine	Mirtazapine	14	suppressed
Alendronate Sodium	Alendronate Sodium	13	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	13	suppressed
Nabumetone	Nabumetone	13	suppressed
Nebivolol Hcl	Nebivolol Hcl	13	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	13	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	12	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	11
Bupropion Xl	Bupropion Hcl	11	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error